A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.
Dr. John Cush RheumNow
3 years 4 months ago
Assessing CV Risk in Inflammatory Arthritis: Which Score?
Dr. Aurelie Najm discusses OP0267 presented at EULAR 2023 in Milan, Italy. @AurelieRheumo
https://t.co/qlJ9iMwrip
@AurelieRheumo https://t.co/Yh2siy6555
Dr. John Cush RheumNow
3 years 4 months ago
Abatacept: is there a role before RA hits?
Dr. David Liew discusses OP0130 at EULAR 2023 in Milan, Italy. @drdavidliew
https://t.co/SPLOCjjhUt https://t.co/wkPJLz9ctg
Dr. John Cush RheumNow
3 years 4 months ago
ANCA-associated vasculitis: beyond therapy with rituximab?
AAV is a group of multi-system autoimmune small vessel vasculitides which includes GPA, MPA and EGPA.
https://t.co/eZ3mgdjrEp https://t.co/dM9B4tVgmr
Dr. John Cush RheumNow
3 years 4 months ago
Methotrexate - an old trusted friend who deserves better
MTX has been used as the anchor drug for the treatment of RA and PsA for many years. It has been co-prescribed with biologics and JAKi in clinical trials and as well as in clinical practice.
https://t.co/xp40KklMkA https://t.co/oVqzlQeqbe
Dr. John Cush RheumNow
3 years 4 months ago
RheumNow Eular2023 Coverage - SLE Panel Discussion https://t.co/pLWOqZo2aw https://t.co/itAOjgmMTl
Dr. John Cush RheumNow
3 years 4 months ago
AOSD: Young vs. Elderly Onset
AOSDis an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million.
https://t.co/fg5TakEvvv https://t.co/lu34gX7WTZ
Dr. John Cush RheumNow
3 years 4 months ago
EULAR 2023 Notes from Milan
Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy
https://t.co/brcgGv2GHD https://t.co/zVyZkEuLy4
Dr. John Cush RheumNow
3 years 4 months ago
Assessing CV Risk in Inflammatory Arthritis: Which Score?
Dr. Aurelie Najm discusses OP0267 presented at EULAR 2023 in Milan, Italy.
https://t.co/MvqkKya4vm
@AurelieRheumo
Dr. John Cush RheumNow
3 years 4 months ago
Combining a Tyk2 inhibitor with a JAKi in RA?
Dr. Janet Pope (@Janetbirdope ) weighs in on #EULAR23 abstracts.
https://t.co/7fTZjvnHT3 https://t.co/o43VrWpVpI
Dr. John Cush RheumNow
3 years 4 months ago
A step change towards self-empowerment for people living with SLE
As I reflect on my research journey, I recall several issues that still need to be addressed in the management of SLE.
https://t.co/ElunbUgSGF https://t.co/YmA1YWPxVP
Dr. John Cush RheumNow
3 years 4 months ago
Postpartum Depression in RA
Dr. Jonathan Kay discusses abstract POS0206-HPR at EULAR 2023 in Milan, Italy.
https://t.co/dzUMIia8Q6 https://t.co/IjeEvz8Cab
Dr. John Cush RheumNow
3 years 4 months ago
The Importance of Identifying Central Pain in PsA
Dr. Eric Ruderman discusses abstracts OP0068 and OP0299 at EULAR 2023 in Milan, Italy.
https://t.co/5fjNTrQvNx https://t.co/E1ivkK2bFz

